COMPANY PROFILE

Calluna Pharma

Explore full profile

Creating pioneering treatments to combat chronic inflammation and fibrosis from their root causes

Oslo, NorwayFounded 2024Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Calluna Pharma

Calluna Pharma is a clinical-stage biotechnology company that specializes in the development of therapies for inflammatory and fibrotic diseases. The company is focused on creating selective antibodies that target immunological diseases with enhanced efficacy. Their pipeline includes several first-in-class clinical candidates, with their lead product being CAL101, which has completed a Phase 1 clinical study for fibrotic and fibro-inflammatory indications. Calluna Pharma operates in the biotechnology market, a sector characterized by high research and development costs and long product development timelines. The company's business model is centered on the discovery and clinical development of novel drug candidates. Their revenue generation will likely depend on partnerships with larger pharmaceutical companies for further development, manufacturing, and commercialization, or through the eventual sale of their developed therapies. The company has recently secured significant funding through a €75 million Series A financing round, which will support the advancement of its product pipeline.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2024
Headquarters: Oslo, Norway
Employees: 27
Open positions: 1
Dealroom signal: 86.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jan 2024	$83M	$330M	Investinor · Sarsia · Forbion Capital Partners · p53 Invest	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Calluna Pharma website traffic

Latest recorded traffic for Calluna Pharma is 1.9K monthly website visits, up 46.2% over the last three months. Calluna Pharma's team grew 12.5% over the past year.

Latest monthly visits1.9K 3-month web change+46.2% 1-year team growth+12.5%

Monthly website visitsJan 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Administrative CoordinatorOslo, Norway · Human Resources · Jun 20, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
ABAvenue BiosciencesInnovative protein engineering solutions integrating biologics and machine learning for therapeutic advancements	Palo Alto, United States	Operational
NDNexus DynamixBringing space to Earth: AI-powered microgravity for drug discovery, oncology, and regenerative medicine	Vilnius, Lithuania	Operational
ALALLOXHarnessing the power of genetics and AI to learn the biophysical parameters governing protein function	Barcelona, Spain	Operational
VTVRG TherapeuticsVRG Therapeutics is a regional leader in biopharmaceutical R&D with a world-class protein evolution tech platform for CGT applications	Budapest, Hungary	Operational
CRCradleAI-powered protein design and engineering platform.	Amsterdam, Netherlands	Operational
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational
EPEpitopeaTransatlantic cancer immunotherapeutics company	Montreal, Canada	Operational